ATA901196A - Verwendung von aktiviertem protein c zur herstellung einer pharmazeutischen präparation - Google Patents

Verwendung von aktiviertem protein c zur herstellung einer pharmazeutischen präparation

Info

Publication number
ATA901196A
ATA901196A AT0901196A AT901196A ATA901196A AT A901196 A ATA901196 A AT A901196A AT 0901196 A AT0901196 A AT 0901196A AT 901196 A AT901196 A AT 901196A AT A901196 A ATA901196 A AT A901196A
Authority
AT
Austria
Prior art keywords
pharmaceutical preparation
producing
activated protein
protein
inflammations
Prior art date
Application number
AT0901196A
Other languages
English (en)
Other versions
AT409822B (de
Inventor
Johann Eibl
Ludwig Pichler
Hans-Peter Schwarz
Peter Turecek
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno Ag filed Critical Immuno Ag
Publication of ATA901196A publication Critical patent/ATA901196A/de
Application granted granted Critical
Publication of AT409822B publication Critical patent/AT409822B/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AT0901196A 1995-01-20 1996-01-12 Verwendung von aktiviertem protein c zur herstellung einer pharmazeutischen präparation AT409822B (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/375,777 US5571786A (en) 1990-08-16 1995-01-20 Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
PCT/EP1996/000126 WO1996022108A1 (en) 1995-01-20 1996-01-12 The use of activated protein c for preparing a pharmaceutical preparation

Publications (2)

Publication Number Publication Date
ATA901196A true ATA901196A (de) 2002-04-15
AT409822B AT409822B (de) 2002-11-25

Family

ID=23482293

Family Applications (2)

Application Number Title Priority Date Filing Date
AT0901196A AT409822B (de) 1995-01-20 1996-01-12 Verwendung von aktiviertem protein c zur herstellung einer pharmazeutischen präparation
AT96901265T ATE218368T1 (de) 1995-01-20 1996-01-12 Medikament welches protein c aktivierendes peptid enthält

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT96901265T ATE218368T1 (de) 1995-01-20 1996-01-12 Medikament welches protein c aktivierendes peptid enthält

Country Status (9)

Country Link
US (1) US5571786A (de)
EP (1) EP0804228B1 (de)
JP (1) JP3330953B2 (de)
AT (2) AT409822B (de)
CA (1) CA2209931A1 (de)
DE (1) DE69621591T2 (de)
DK (1) DK0804228T3 (de)
ES (1) ES2177755T3 (de)
WO (1) WO1996022108A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001526533A (ja) 1997-04-23 2001-12-18 フラームス・インテルウニフェルシタイル・インスティチュート・フォール・ビオテヒノロヒー λ様プロモーターを有する遺伝子の誘導性発現のための調節系
US6953568B1 (en) * 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
CA2358492A1 (en) * 1998-12-21 2000-06-29 Eli Lilly And Company Combination therapy for the treatment of sepsis
EP1353702A2 (de) * 2000-05-22 2003-10-22 The Johns Hopkins University Genmanipulation der gefässtransplantat zur resistenz gegen erkrankungen
ATE550073T1 (de) * 2001-06-13 2012-04-15 Univ Sydney Protein c für die wundheilung
EP1417055A4 (de) * 2001-07-19 2007-09-26 Dmi Biosciences Inc Verwendung von kupferchelatoren zur verhinderung der inaktivierung von protein c
US7982008B2 (en) 2002-11-27 2011-07-19 David Bar-Or Treatment of diseases and conditions mediated by increased phosphorylation
DK2857037T3 (da) 2012-05-31 2019-07-22 Univ Kinki Middel til forebyggelse og/eller behandling af perifere neuropatiske smerter forårsaget af anticancerlægemiddel
JP6273272B2 (ja) 2012-07-04 2018-01-31 ジージー バイオテック エルエルシー 炎症性皮膚障害の治療
ES2890623T3 (es) 2014-04-16 2022-01-20 Zz Biotech Llc Uso del análogo de APC para curar heridas
DK3137102T3 (da) 2014-04-16 2021-10-11 Zz Biotech Llc Apc til anvendelse til behandling af unormal kutan ardannelse
CA3112679A1 (en) 2018-09-28 2020-04-02 Asahi Kasei Pharma Corporation Medicament for mitigating conditions and/or suppressing onset of peripheral neuropathy induced by anti-malignant tumor agent

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU185926B (en) * 1979-09-27 1985-04-28 Agostne Kahan Process for preparing water soluble derivatives of non-steroid antiinflammatory compositions and pharmaceutical compositins containing such derivatives
GB8319538D0 (en) * 1983-07-20 1983-08-24 Beecham Group Plc Compounds
US4658830A (en) * 1984-08-08 1987-04-21 Survival Technology, Inc. Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms
US4902614A (en) * 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4849403A (en) * 1985-05-29 1989-07-18 Pentapharm Ag Protein C activator, methods of preparation and use thereof
US4908314A (en) * 1987-07-02 1990-03-13 American National Red Cross Protein C activator
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US5009889A (en) * 1987-12-31 1991-04-23 Oklahoma Medical Research Foundation Treatment of dysfunctional vascular endothelium using activated protein C
JP2739050B2 (ja) * 1988-01-28 1998-04-08 ヘキスト薬品工業株式会社 抗血液凝固剤
DE3804600A1 (de) * 1988-02-13 1989-08-24 Basf Ag Mischung aus einer thrombolytisch wirkenden und einer antithrombotischen substanz
US5093117A (en) * 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
JP2774156B2 (ja) * 1989-09-05 1998-07-09 帝人株式会社 ヒトプロテインｃおよび／または活性化ヒトプロテインｃ様活性を有する蛋白
AT402260B (de) * 1990-08-16 1997-03-25 Immuno Ag Protein c-hältige pharmazeutische präparation

Also Published As

Publication number Publication date
ATE218368T1 (de) 2002-06-15
WO1996022108A1 (en) 1996-07-25
ES2177755T3 (es) 2002-12-16
EP0804228A1 (de) 1997-11-05
JP3330953B2 (ja) 2002-10-07
DE69621591D1 (de) 2002-07-11
DE69621591T2 (de) 2003-01-16
JPH11502508A (ja) 1999-03-02
EP0804228B1 (de) 2002-06-05
AT409822B (de) 2002-11-25
US5571786A (en) 1996-11-05
DK0804228T3 (da) 2002-09-23
CA2209931A1 (en) 1996-07-25

Similar Documents

Publication Publication Date Title
DE3888274D1 (de) Vorrichtung zur intensiven und kontrollierten Herstellung von Mikroorganismen durch Photosynthese.
ATE456648T1 (de) Verfahren zur herstellung von l-aminosäure
EP0670369A3 (de) An menschliches programmiertes Zelltod relatiertes Peptid, und dessen kodierende DNA
ES2162132T3 (es) Polimerasa de adn termoestable procedente de thermoanaerobacter thermohydrosulfuricus y enzimas mutantes, de actividad exonucleasa suprimida asi obtenidos.
DE3585542D1 (de) Methoden zur herstellung biologisch aktiver membranen und ihre verwendungen.
EP0251584A3 (de) Synchronisationsverwaltung für ein verteiltes Betriebssystem oder ähnliche Systeme
DE69113386D1 (de) Herstellung von Medikamenten zur Behandlung von Asthma, unter Verwendung von (S)-Alpha-Fluoromethyl-Histidin und dessen Estern.
FR2695714B1 (fr) Installation de traitement cryogénique, notamment de distillation d'air.
DK0804228T3 (da) Lægemiddel indeholdende aktiveringspeptidet for protein C
CA2006087A1 (en) Polypeptides isolated from the venom of the spider hololena curta
DE3789309D1 (de) Enzymatische membran, verfahren zur herstellung und trennung von peptiden.
CA2131565A1 (en) Organopolysiloxanes Containing Hydrophilic Groups
AU1384995A (en) Human circulating cytokine cc-1
DE3769096D1 (de) Verfahren zur herstellung einer faktor viii (ahf)-haeltigen fraktion.
ATE227307T1 (de) Verfahren zur herstellung modifizierten proteine
AU4876196A (en) A process for the preparation of factor ix from biological sources
CA2041380A1 (en) Use of protein c or activated protein c for preparing a pharmaceutical preparation
DE58903876D1 (de) Riboflavin-4'5'-cyclo-phosphorsaeureesterchlorid, dessen herstellung und verwendung zur herstellung von riboflavin-5'-phosphat (5'-fmn) bzw. dessen natriumsalz.
ATE207116T1 (de) Methode zur reinigung einer wässrigen enzymlösung
KR950700988A (ko) 미생물, 이들의 제조방법 및 이들의 사용(Micro-organisms, preparation method therefor and uses thereof)
DE59410423D1 (de) Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
AU4312093A (en) Use of a hymenoptera venom for the manufacture of a medicament for treating dna virus infections
DE69310343D1 (de) Blutverarbeitungssysteme mit verbesserter ausbeute und methoden zur herstellung von vortexströmungsbedingungen
BR9609801A (pt) Petídos cíclicos análogos de somatostina com atividade inibitória do desenvolvimento de hormónio
DE69838615D1 (de) ppGpp-SYNTHETASE UND EXPRESSIONSSYSTEME ZUR VERBESSERTEN HERSTELLUNG VON PROTEINEN

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee